Join to view full profile
988102 Nebraska Medical CtrOmaha, NE 68198
Phone+1 402-559-4015
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Schwarz, MD is an oncologist in Omaha, Nebraska. He is currently licensed to practice medicine in Nebraska, Iowa, and New York. He is an Assistant Professor at University of Nebraska Medical.
Education & Training
University of Missouri-ColumbiaFellowship, Hematology and Medical Oncology, 1998 - 2001
Duke University HospitalFellowship, Infectious Disease, 1990 - 1994- Duke University HospitalResidency, Internal Medicine, 1987 - 1990
Duke University School of MedicineClass of 1987
Certifications & Licensure
IA State Medical License 2025 - 2027
NE State Medical License 2008 - 2026
MO State Medical License 1998 - 2021
NY State Medical License 2001 - 2008
NC State Medical License 1989 - 1995
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013-2017
Publications & Presentations
PubMed
- 30 citationsPhase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003Arkadiusz Z. Dudek, Li C Liu, Shilpa Gupta, Theodore F. Logan, Eric A. Singer
Journal of Clinical Oncology. 2020-02-25 - 65 citationsRamucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): ove...Daniel P. Petrylak, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg
The Lancet. Oncology. 2020-01-01 - 18 citationsPhase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarc...Chi Lin, Vivek Verma, Audrey J. Lazenby, Quan P. Ly, Lyudmyla Berim
American Journal of Clinical Oncology. 2019-10-01
